article thumbnail

SEC recommends permission to SII for Omicron XBB 1.5 variant Covid-19 vaccine

AuroBlog - Aurous Healthcare Clinical Trials blog

A Subject Expert Committee (SEC), which advices the national drug regulator on approvals and clinical trials related to Covid-19 vaccines, has recommended grant of permission to Serum Institute of India (SII) for Omicron XBB 1.5 The vaccine variant […]

article thumbnail

SEC recommends approval for Zydus Lifesciences’ trivalent influenza vaccine in children

AuroBlog - Aurous Healthcare Clinical Trials blog

The Subject Expert Committee (SEC), which advises the Central drug regulator regarding clinical trials and approvals of drugs, has recommended approval for additional indication of Zydus Lifesciences’ inactivated trivalent influenza vaccine in children above six months with clinical trial waiver subject to condition.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Experimental Alzheimer’s Vaccine Shown to Delay Symptoms in Mice

AuroBlog - Aurous Healthcare Clinical Trials blog

An experimental vaccine that aims to slow down or prevent the progression of Alzheimer’s disease has been trialed in mice with promising early results. Mice engineered with genes that put them at greater risk of an Alzheimer’s-like disease had fewer amyloid plaques following the vaccine.

article thumbnail

Malaria Could Be Eliminated by 2040: New Vaccine Offers Hope

AuroBlog - Aurous Healthcare Clinical Trials blog

The World Health Organization has approved a new vaccine that scientists argue will be a game-changer in the fight against malaria, which kills half a million people in Africa every year.

article thumbnail

Velocity Wins the 2024 Vaccine Industry Excellence Award for Best Clinical Trial Company

Velocity Clinical Research

Velocity has won the 2024 Vaccine Industry Excellence (ViE) award for Best Clinical Trial Company at The World Vaccine Congress in Washington, DC. The recognition is based on performance metrics, diversity of vaccine trial capabilities, and key initiatives to support vaccine research.

article thumbnail

Study shines a light on representation in clinical research

Drug Discovery World

A diversity study has shown that clinical trials should use real world diseases epidemiology data, rather than US Census Bureau race and ethnicity data, to ensure enrolment reflects the populations affected by different diseases. It also showed that GSK trial enrolment for each condition differed by race and ethnicity.

article thumbnail

Vaccines and various response rates

Drug Discovery World

DDW Editor Reece Armstrong speaks to Dr Katrina Pollock from the Oxford Vaccine Group at the University of Oxford. Dr Pollock is the Chief Investigator of the LEGACY03 clinical trial, a study aiming to investigate lymph nodes and vaccination responses across age groups. RA: Could you tell us about the LEGACY03 trial?